Lilly's weekly prescription data for Zepbound is up 354% year-over-year, while Novo's Wegovy is up just 61%. That's based on ...

The World Health Organisation plans to officially back the use of weight-loss drugs to treat obesity in adults for the first ...

Eli Lilly reported a strong revenue jump driven by the blockbuster performance of its weight loss and diabetes drugs, ...

Eli Lilly shares dropped Thursday as Novo Nordisk notched a coverage win for its obesity drug, a sign of the competition in ...

Eli Lilly & Co. cut its earnings outlook on research charges and maintained its full-year sales guidance as its blockbuster ...

LONDON (Reuters) -The World Health Organization plans to officially back the use of weight-loss drugs to treat obesity in ...

Eli Lilly said sales of weight loss drug Zepbound and diabetes treatment Mounjaro soared in the first quarter.

The World Health Organization plans to endorse weight-loss drugs for treating adult obesity, marking a shift in addressing ...

FILE PHOTO: Vials of Eli Lilly's Mounjaro, a tirzepatide injection drug used for treating type 2 diabetes and weight loss, ...

Eli Lilly on Thursday posted better-than-expected quarterly results, although sales of its popular weight-loss drug, Zepbound ...